U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C25H31N9O2.C4H8O2
Molecular Weight 1067.2506
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Golidocitinib hemi-ethyl acetate solvate

SMILES

CCOC(C)=O.COC1=NN(C)C=C1NC2=NC=CC(=N2)C3=CNC4=C3C=CC=C4NC(=O)[C@@H](C)N5CCN(C)CC5.COC6=NN(C)C=C6NC7=NC=CC(=N7)C8=CNC9=C8C=CC=C9NC(=O)[C@@H](C)N%10CCN(C)CC%10

InChI

InChIKey=ZLKJCHKHIZOEFG-XQAUMGQKSA-N
InChI=1S/2C25H31N9O2.C4H8O2/c2*1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4;1-3-6-4(2)5/h2*5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30);3H2,1-2H3/t2*16-;/m11./s1

HIDE SMILES / InChI
Molecular Formula C25H31N9O2
Molecular Weight 489.5727
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H8O2
Molecular Weight 88.1051
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
149124
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.14 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18.6 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
48.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
133 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
232 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
33.8 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
62.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
149 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
83.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
169 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
375 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
923 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2340 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5260 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7260 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
536 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1020 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2490 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1530 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3190 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7190 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
51.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
42.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
50.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
46.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
37%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37077916/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GOLIDOCITINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Substance Class Chemical
Created
by admin
on Tue Apr 01 23:24:28 GMT 2025
Edited
by admin
on Tue Apr 01 23:24:28 GMT 2025
Record UNII
NS94P621A0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-4205 hemi-ethyl acetate solvate
Preferred Name English
Golidocitinib hemi-ethyl acetate solvate
Common Name English
(R)-N-(3-(2-((3-METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO)PYRIMIDIN-4-YL)-1H-INDOL-7-YL)-2-(4- METHYLPIPERAZIN-1-YL)PROPANAMIDE HEMI ETHYL ACETATE SOLVATE
Systematic Name English
AZD4205 hemi-ethyl acetate solvate
Code English
Acetic acid, ethyl ester, compd. with (?R)-N-[3-[2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-1H-indol-7-yl]-?,4-dimethyl-1-piperazineacetamide (1:2)
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 763220
Created by admin on Tue Apr 01 23:24:28 GMT 2025 , Edited by admin on Tue Apr 01 23:24:28 GMT 2025
Code System Code Type Description
FDA UNII
NS94P621A0
Created by admin on Tue Apr 01 23:24:28 GMT 2025 , Edited by admin on Tue Apr 01 23:24:28 GMT 2025
PRIMARY
PUBCHEM
163203546
Created by admin on Tue Apr 01 23:24:28 GMT 2025 , Edited by admin on Tue Apr 01 23:24:28 GMT 2025
PRIMARY
CAS
2091135-65-6
Created by admin on Tue Apr 01 23:24:28 GMT 2025 , Edited by admin on Tue Apr 01 23:24:28 GMT 2025
PRIMARY
SMS_ID
300000007981
Created by admin on Tue Apr 01 23:24:28 GMT 2025 , Edited by admin on Tue Apr 01 23:24:28 GMT 2025
PRIMARY
Related Record Type Details
Structure of Golidocitinib
ANHYDROUS->SOLVATE
Structure of Golidocitinib
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Golidocitinib
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966